The FDA granted accelerated approval to infigratinib, a kinase inhibitor approved for adults with previously treated, locally advanced, unresectable, or metastatic CCA with an FGFR2 gene fusion or rearrangement [19]. This evidence concerns the gene FGFR2 and cholangiocarcinoma.